Background: Synbiotic supplements that integrate prebiotics, probiotics, and postbiotic substances are progressively utilized to enhance gastrointestinal wellbeing. Colonzak® comprises calcium butyrate, fructo-oligosaccharides (FOS), and two probiotic strains: Bifidobacterium bifidum Bb-06 and Bifidobacterium lactis Bl-04. A thorough safety assessment is necessary to endorse its clinical and consumer application.

Methods: A qualitative review was performed utilizing product formulation data, regulatory documents, and published scientific literature. Each component was assessed for toxicological safety, regulatory compliance, and clinical tolerability. Dosage recommendations were evaluated in relation to defined safe intake ranges.

Results: All active compounds exhibited robust safety profiles corroborated by EFSA and FDA standards. Calcium butyrate is well tolerated at doses considerably higher than those utilized in Colonzak®. FOS consumption remains well below levels linked to gastrointestinal discomfort.

Both probiotic strains are listed in the EFSA Qualified Presumption of Safety (QPS) and have been confirmed through clinical research, demonstrating no major side effects. The advised dosage (1–2 capsules per day) is within recognized safe and effective limits.

Conclusion: Colonzak® is deemed safe for administration in adults and adolescents aged 12 years and older when utilized according to the prescribed guidelines. The formulation aligns with contemporary scientific evidence and regulatory criteria. Longitudinal and population- specific research are advised.